Back to Journals » Vascular Health and Risk Management » Volume 5

Improving outcomes in patients undergoing percutaneous coronary intervention: role of prasugrel

Authors Motovska Z, Widimsky P

Published 21 May 2009 Volume 2009:5 Pages 475—481


Review by Single anonymous peer review

Peer reviewer comments 2

Zuzana Motovska, Petr Widimsky

Third Medical Faculty of Charles University and University Hospital Kralovske Vinohrady, Prague, Czech Republic

Abstract: Dual oral antiplatelet therapy, aspirin plus thienopyridine, has permitted a rapid increase in the use of coronary intervention procedures. Clopidogrel is the thienopyridine of choice for dual antiplatelet therapy in patients treated with percutaneous coronary intervention. However, there are two issues with clopidogrel: (1) clopidogrel’s antiplatelet activity is delayed because the drug needs to be metabolized into its active form and (2) variability in patient response to clopidogrel has been demonstrated. To overcome these shortcomings of clopidogrel, new more potent inhibitors of P2Y12 receptors, which have a more rapid onset of action have been introduced for clinical evaluation. This article is a nonexhaustive review of the literature and concentrates on prasugrel, a third-generation, oral thienopyridine. The purpose is to summarize the current knowledge about the benefits and risks of prasugrel and to outline the most prudent strategies for the drug’s clinical use.

Keywords: P2Y12 receptors, prasugrel, oral thienopyridine, dual oral antiplatelet therapy

Creative Commons License © 2009 The Author(s). This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.